Des études montrent que le tabagisme peut être un facteur de risque pour divers cancers, y compris le sein.
TabagismeFacteurs de risqueCarcinome intracanalaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Carcinome intracanalaire non infiltrant : Questions médicales les plus fréquentes",
"headline": "Carcinome intracanalaire non infiltrant : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Carcinome intracanalaire non infiltrant : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-02",
"dateModified": "2025-12-22",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Carcinome intracanalaire non infiltrant"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs canalaires, lobulaires et médullaires",
"url": "https://questionsmedicales.fr/mesh/D018299",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs canalaires, lobulaires et médullaires",
"code": {
"@type": "MedicalCode",
"code": "D018299",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.615"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Maladie de Paget du sein",
"alternateName": "Paget's Disease, Mammary",
"url": "https://questionsmedicales.fr/mesh/D010144",
"about": {
"@type": "MedicalCondition",
"name": "Maladie de Paget du sein",
"code": {
"@type": "MedicalCode",
"code": "D010144",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.470.615.275.625"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Carcinome intracanalaire non infiltrant",
"alternateName": "Carcinoma, Intraductal, Noninfiltrating",
"code": {
"@type": "MedicalCode",
"code": "D002285",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Toyonori Tsuzuki",
"url": "https://questionsmedicales.fr/author/Toyonori%20Tsuzuki",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgical Pathology, Aichi Medical University, School of Medicine, Nagakute, Japan."
}
},
{
"@type": "Person",
"name": "Brett Delahunt",
"url": "https://questionsmedicales.fr/author/Brett%20Delahunt",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago Wellington, Wellington, New Zealand."
}
},
{
"@type": "Person",
"name": "Hemamali Samaratunga",
"url": "https://questionsmedicales.fr/author/Hemamali%20Samaratunga",
"affiliation": {
"@type": "Organization",
"name": "Aquesta Uropathology, University of Queensland, Brisbane, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Dominique Trudel",
"url": "https://questionsmedicales.fr/author/Dominique%20Trudel",
"affiliation": {
"@type": "Organization",
"name": "Centre de Recherche du Centre Hospitalier de l'Université de Montréal (axe Cancer) and Institut du Cancer de Montréal, 900 Saint-Denis, Montréal, QC H2X 0A9, Canada."
}
},
{
"@type": "Person",
"name": "Glen Kristiansen",
"url": "https://questionsmedicales.fr/author/Glen%20Kristiansen",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Hospital Bonn, 53127 Bonn, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Detection of intraductal carcinoma in prostate cancer patients with small tumor volume.",
"datePublished": "2023-02-10",
"url": "https://questionsmedicales.fr/article/36762419",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/pros.24492"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pure Apocrine Intraductal Carcinoma of Salivary Glands: Reassessment of Molecular Underpinnings and Behavior.",
"datePublished": "2024-06-27",
"url": "https://questionsmedicales.fr/article/38935197",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12105-024-01653-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "PTEN loss in intraductal carcinoma of the prostate has low incidence in Japanese patients.",
"datePublished": "2023-08-23",
"url": "https://questionsmedicales.fr/article/37608749",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/pin.13369"
}
},
{
"@type": "ScholarlyArticle",
"name": "Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread.",
"datePublished": "2023-06-20",
"url": "https://questionsmedicales.fr/article/37422404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pathol.2023.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comedonecrosis within conventional prostatic adenocarcinoma vs. intraductal carcinoma of the prostate: their clinical significance is not comparable.",
"datePublished": "2023-06-24",
"url": "https://questionsmedicales.fr/article/37364826",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.humpath.2023.06.011"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs épithéliales épidermoïdes et glandulaires",
"item": "https://questionsmedicales.fr/mesh/D009375"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tumeurs canalaires, lobulaires et médullaires",
"item": "https://questionsmedicales.fr/mesh/D018299"
},
{
"@type": "ListItem",
"position": 6,
"name": "Carcinome intracanalaire non infiltrant",
"item": "https://questionsmedicales.fr/mesh/D002285"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Carcinome intracanalaire non infiltrant - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Carcinome intracanalaire non infiltrant",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Carcinome intracanalaire non infiltrant",
"description": "Comment diagnostique-t-on un carcinome intracanalaire non infiltrant ?\nQuels examens d'imagerie sont utilisés ?\nQuels sont les signes radiologiques typiques ?\nLa biopsie est-elle toujours nécessaire ?\nPeut-on détecter ce carcinome par auto-examen ?",
"url": "https://questionsmedicales.fr/mesh/D002285#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Carcinome intracanalaire non infiltrant",
"description": "Quels sont les symptômes du carcinome intracanalaire ?\nY a-t-il des douleurs associées ?\nLes changements cutanés sont-ils fréquents ?\nLes ganglions lymphatiques sont-ils affectés ?\nPeut-on avoir des symptômes sans masse palpable ?",
"url": "https://questionsmedicales.fr/mesh/D002285#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Carcinome intracanalaire non infiltrant",
"description": "Comment prévenir le carcinome intracanalaire ?\nLe dépistage est-il efficace ?\nY a-t-il des facteurs de risque modifiables ?\nLes antécédents familiaux influencent-ils le risque ?\nLes traitements hormonaux augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D002285#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Carcinome intracanalaire non infiltrant",
"description": "Quels traitements sont disponibles ?\nLa radiothérapie est-elle nécessaire ?\nDes médicaments sont-ils prescrits ?\nQuelle est l'importance de la surveillance post-traitement ?\nPeut-on éviter la chirurgie ?",
"url": "https://questionsmedicales.fr/mesh/D002285#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Carcinome intracanalaire non infiltrant",
"description": "Quelles complications peuvent survenir ?\nLe carcinome intracanalaire peut-il évoluer ?\nY a-t-il des effets secondaires des traitements ?\nComment gérer les complications ?\nLes complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D002285#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Carcinome intracanalaire non infiltrant",
"description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nLes facteurs environnementaux sont-ils importants ?\nLe tabagisme influence-t-il le risque ?",
"url": "https://questionsmedicales.fr/mesh/D002285#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un carcinome intracanalaire non infiltrant ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par mammographie, échographie et biopsie des tissus mammaires."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La mammographie et l'échographie sont les examens d'imagerie principaux pour détecter ce type de cancer."
}
},
{
"@type": "Question",
"name": "Quels sont les signes radiologiques typiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "On observe souvent des microcalcifications ou des masses bien définies sur les images."
}
},
{
"@type": "Question",
"name": "La biopsie est-elle toujours nécessaire ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la biopsie est essentielle pour confirmer le diagnostic et évaluer la nature des cellules."
}
},
{
"@type": "Question",
"name": "Peut-on détecter ce carcinome par auto-examen ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'auto-examen peut aider, mais il est souvent asymptomatique et nécessite des examens médicaux."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du carcinome intracanalaire ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, il peut se manifester par des écoulements mamelonnaires ou des masses."
}
},
{
"@type": "Question",
"name": "Y a-t-il des douleurs associées ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Généralement, il n'y a pas de douleur, mais des douleurs peuvent survenir si d'autres conditions sont présentes."
}
},
{
"@type": "Question",
"name": "Les changements cutanés sont-ils fréquents ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des changements cutanés peuvent survenir, mais ils sont plus souvent associés à d'autres types de cancer."
}
},
{
"@type": "Question",
"name": "Les ganglions lymphatiques sont-ils affectés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "En général, le carcinome intracanalaire non infiltrant n'affecte pas les ganglions lymphatiques."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans masse palpable ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut y avoir des symptômes comme des écoulements sans masse palpable détectable."
}
},
{
"@type": "Question",
"name": "Comment prévenir le carcinome intracanalaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut un dépistage régulier et un mode de vie sain, comme une alimentation équilibrée."
}
},
{
"@type": "Question",
"name": "Le dépistage est-il efficace ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le dépistage précoce par mammographie peut réduire la mortalité liée au cancer du sein."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque modifiables ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le contrôle du poids, l'exercice régulier et l'évitement de l'alcool peuvent aider."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancer du sein augmentent le risque de développer ce carcinome."
}
},
{
"@type": "Question",
"name": "Les traitements hormonaux augmentent-ils le risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements hormonaux peuvent augmenter le risque de cancer du sein, y compris le carcinome intracanalaire."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la chirurgie, souvent une tumorectomie, suivie d'une surveillance."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La radiothérapie peut être recommandée après la chirurgie pour réduire le risque de récidive."
}
},
{
"@type": "Question",
"name": "Des médicaments sont-ils prescrits ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments hormonaux peuvent être prescrits si le cancer est hormono-dépendant."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance post-traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour détecter toute récidive ou complication éventuelle."
}
},
{
"@type": "Question",
"name": "Peut-on éviter la chirurgie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est généralement nécessaire, mais des options de surveillance active peuvent être discutées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la récidive du cancer et des effets secondaires des traitements."
}
},
{
"@type": "Question",
"name": "Le carcinome intracanalaire peut-il évoluer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, sans traitement, il peut évoluer vers un carcinome infiltrant, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des traitements ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires comme la fatigue, des douleurs et des nausées."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite un suivi médical régulier et un soutien psychologique."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications et les effets secondaires des traitements peuvent affecter la qualité de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'âge, le sexe féminin, les antécédents familiaux et les mutations génétiques."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire, l'obésité et la consommation d'alcool augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies mammaires ou de traitements hormonaux augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils importants ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains produits chimiques et radiations peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que le tabagisme peut être un facteur de risque pour divers cancers, y compris le sein."
}
}
]
}
]
}
Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago Wellington, Wellington, New Zealand.
Publications dans "Carcinome intracanalaire non infiltrant" :
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (axe Cancer) and Institut du Cancer de Montréal, 900 Saint-Denis, Montréal, QC H2X 0A9, Canada.
Department of Pathology and Cellular Biology, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC H3T 1J4, Canada.
Department of Pathology, Centre Hospitalier de l'Université de Montréal, 1051 Sanguinet, Montréal, QC H2X 0C1, Canada.
Publications dans "Carcinome intracanalaire non infiltrant" :
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: liang_cheng@yahoo.com.
Publications dans "Carcinome intracanalaire non infiltrant" :
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (axe Cancer) and Institut du Cancer de Montréal, 900 Saint-Denis, Montréal, QC H2X 0A9, Canada.
Department of Pathology and Cellular Biology, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC H3T 1J4, Canada.
Publications dans "Carcinome intracanalaire non infiltrant" :
Department of Laboratory Medicine and Pathobiology, University Health Network, 200 Elizabeth Street, Toronto, Ontario M5G 2C4, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. Electronic address: ILAN.WEINREB@UHN.CA.
Publications dans "Carcinome intracanalaire non infiltrant" :
The purpose of this study was to investigate intraductal carcinoma of the prostate (intraductal carcinoma) and significant cancer (SC) in patients with small tumor volume (<0.5 cm...
Data from 639 patients undergoing radical prostatectomy between April 2006 and December 2017 at Chiba University Hospital and 2 affiliated institutions were retrospectively reviewed. Tumor volume in p...
A total of 83 patients with tumor volume < 0.5 cm...
The results of the present study suggest that intraductal carcinoma was present even in cases with small tumor volumes. Grade Group and intraductal carcinoma showed a positive correlation with tumor v...
Intraductal carcinoma (IDC) of the salivary glands is a confounding entity, our understanding of which continues to evolve. At least four forms have been elucidated based on histomorphology, immunophe...
IDCs with pure apocrine morphology, entirely intraductal growth, and no precursor lesion (pleomorphic adenoma or sclerosing polycystic adenoma) were retrieved from the authors' archives. Several immun...
Seven entirely IDC with pure apocrine type were collected. The cases arose in the parotid glands (mean, 1.9 cm) of 5 men and 2 women ranging from 51 to 84 years (mean, 69.7 years). Histologically, tum...
Purely apocrine IDC is a heterogeneous disease. A subset seems to be genetically similar to salivary duct carcinoma and may indeed represent carcinoma in situ. The other group harbors fusions, similar...
Clinical and genomic features of prostate cancer (PCa) vary considerably between Asian and Western populations. PTEN loss is the most frequent abnormality in intraductal carcinoma of the prostate (IDC...
The presence of intraductal carcinoma of the prostate (IDCP) correlates with late-stage disease and poor outcomes for patients with prostatic adenocarcinoma, but the accurate and reliable staging of d...
It remains controversial if Gleason grade should be assigned to intraductal carcinoma of the prostate (IDC-P) and if the prognostic value of comedonecrosis associated with IDC-P is equivalent to that ...
Breast papillary neoplasms include a wide range of tumor types, and their pathological diagnosis is sometimes difficult. Furthermore, the etiology of these lesions is still not fully understood. We re...
Axillary evaluation is unnecessary for pure ductal carcinoma in situ (DCIS); however, it is performed because of the risk of upstaging to invasive cancer. We assessed the role of intraoperative frozen...
We reviewed patients with preoperative DCIS who underwent breast-conserving surgery (BCS) with IOF biopsy. Positive IOF biopsy findings were defined as the presence of invasive or micro-invasive cance...
Seventy-eight patients underwent BCS with IOF biopsy. Six patients showed positive IOF biopsy findings; five of these patients showed concordant permanent pathology findings. Sentinel lymph node biops...
IOF evaluation can aid in detecting the invasiveness of tumors in patients with preoperative DCIS....
Our objective was to correlate staging PSMA PET imaging parameters to final histopathology. Second objective was to assess the performance of standard versus delayed PSMA PET to detect primary prostat...
Thirty-one patients (mean age, 61.4 ± 8.2) who underwent radical prostatectomy and preoperative staging PSMA PET scans were included in the study. After defining dominant lesion in pathology, correlat...
Dominant lesion SUV's increased with time 8.2(± 4.5), 10(± 7.1), and 10.2(± 7.8) at 1, 2, and 3 h (P = .03 T1-T3). WHO Grade group 3 had highest SUV (group 3 11.9 ± 5.6 vs. group 2 7.9 ± 1.5, p = .02)...
Cribriform pattern correlates with higher Gleason 4 ratios and SUVs in PSMA PET. Intraductal carcinoma is associated with larger tumors but not higher Gleason 4 ratios and SUVs. Multiple late imaging ...
Intraductal carcinoma (IDC) of the prostate is often associated with concurrent high-grade invasive prostate cancer (PCa) and poor clinical outcomes. In this context, IDC is thought to represent the r...
Intraductal carcinoma of the prostate (IDC-P) has emerged as a distinct entity with significant clinical implications in prostate cancer (PCa) management. Despite historically being considered an exte...